Improved glycemic weight control without gain using triple therapy in type 2 diabetes

被引:39
作者
Strowig, SM [1 ]
Avilés-Santa, ML [1 ]
Raskin, P [1 ]
机构
[1] Univ Texas, SW Med Ctr, Dallas, TX 75390 USA
关键词
D O I
10.2337/diacare.27.7.1577
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To evaluate the safety and effectiveness of triple therapy using Insulin, metformin, and thiazolidinedione following a course of dual therapy using insulin and metformin or insulin and a thiazolidinedione in type 2 diabetes. RESEARCH DESIGN AND METHODS - Twenty-eight type 2 diabetic subjects using insulin monothcrapy (baseline HbA(1c) level 8.5%) who had been randomly assigned to insulin (INS) and inetfortnin (MET) (INS + M ET, It = 14) or INS and the Lhiazoliclinedione troghLazone (TGZ) (INS + TGZ, n = 14) (dual therapy) for 4 months were given INS, MET, and TGZ (triple therapy: INS + MET, add TGZ, or INS + TGZ, add MET) for another 4 months. The INS close was not increased. RESULTS - HbA(1c) levels decreased in both groups during dual therapy and improved further during triple therapy (INS+ MET 7.0 +/- 0.8, INS + TGZ 6.2 +/- 0.8, P < 0.0001 INS + MET, acid TGZ 6.1 +/- 04%, P < 0.001 INS + TGZ, add MET 5.8 +/- 0.6%, P < 0.05, and INS + TGZ vs. INS + MET, P = 0.02). Significant reductions In total daily insulin close occurred in the INS + TGZ (- 14.1 units, P < 0.0001), INS + TGZ add MET (- 13.7 units, P < 0.01), and the INS + MET add TGZ aroups (- 17.3 units, P < 0.003), but not in the INS + MET group (-3.2 units) (INS + TCZ vs. INS + MET P < 0.05). Subjects in the INS + TGZ group experienced significant weight gain (4.4 +/- 2.7 kg, P < 0.0005). No weight gain occurred in the INS + MET, INS + MET add TGZ, and INS + TGZ add MET groups. CONCLUSIONS - Triple therapy using INS, MET, and TGZ resulted in lower HbA(1c) levels and total daily insulin dose than during dual therapy. The use of triple therapy resulted in 100% of subjects achieving an HbA(1c) <7.0%, while decreasing the dose of INS. Weight gain was avoided when MET therapy preceded the addition of TGV therapy. The addition of TGZ resulted in the greatesL redUCLIOnS in HbA, levels and insulin close, Triple Lherapy using INS, MET, anct a thiazolidinedione (such as TGZ) can be a safe and effective treatment in type 2 diabetes.
引用
收藏
页码:1577 / 1583
页数:7
相关论文
共 40 条
  • [1] Effects of metformin in patients with poorly controlled insulin-treated type 2 diabetes mellitus -: A randomized, double-blind, placebo-controlled trial
    Avilés-Santa, L
    Sinding, J
    Raskin, P
    [J]. ANNALS OF INTERNAL MEDICINE, 1999, 131 (03) : 182 - +
  • [2] Troglitazone use in insulin-treated type 2 diabetic patients
    Buse, JB
    Gumbiner, B
    Mathias, NP
    Nelson, DM
    Faja, BW
    Whitcomb, RW
    [J]. DIABETES CARE, 1998, 21 (09) : 1455 - 1461
  • [3] Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone
    Buysschaert, M
    Bobbioni, E
    Starkie, M
    Frith, L
    Van Gaal, L
    Somers, G
    Reynders, P
    Buysschaert, M
    Bouillon, R
    Johansen, J
    Gilehuus, RE
    Furuseth, K
    Hansen, AN
    Luhdbo, C
    Caldeira, J
    Saraiva, M
    Correa, N
    Medina, L
    Silva, JL
    Robertson, L
    Lourens, W
    Bonnici, F
    Distiller, L
    Ellis, G
    Gomez, F
    Golay, A
    Suter, S
    Harrower, ADB
    Rayman, G
    Shaw, I
    Simpson, HCR
    Johnston, C
    White, M
    Hepburn, DA
    Beer, SF
    Leatherdale, BA
    Coppack, S
    Hamill, JJ
    Fisher, BM
    [J]. DIABETIC MEDICINE, 1999, 16 (02) : 147 - 153
  • [4] Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance
    Cavaghan, MK
    Ehrmann, DA
    Byrne, MM
    Polonsky, KS
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (03) : 530 - 537
  • [5] Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes
    Chu, NV
    Caulfield, M
    Kong, APS
    Mudaliar, SR
    Kim, DD
    Reitz, R
    Armstrong, D
    Henry, RR
    Baxi, S
    Reaven, PD
    Deutsch, R
    [J]. DIABETES CARE, 2002, 25 (03) : 542 - 549
  • [6] Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: A randomized, double-blind trial
    Dailey, GE
    Noor, MA
    Park, JS
    Bruce, S
    Fiedorek, FT
    [J]. AMERICAN JOURNAL OF MEDICINE, 2004, 116 (04) : 223 - 229
  • [7] Thiazolidinediones: a new class of antidiabetic drugs
    Day, C
    [J]. DIABETIC MEDICINE, 1999, 16 (03) : 179 - 192
  • [8] Pharmacologic therapy for type 2 diabetes mellitus
    DeFronzo, RA
    [J]. ANNALS OF INTERNAL MEDICINE, 1999, 131 (04) : 281 - 303
  • [9] Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes melitus: A randomized, placebo-controlled study
    Einhorn, D
    Rendell, M
    Rosenzweig, J
    Egan, JW
    Mathisen, AL
    Schneider, RL
    [J]. CLINICAL THERAPEUTICS, 2000, 22 (12) : 1395 - 1409
  • [10] β-cell mass dynamics in Zucker diabetic fatty rats -: Rosiglitazone prevents the rise in net cell death
    Finegood, DT
    McArthur, MD
    Kojwang, D
    Thomas, MJ
    Topp, BG
    Leonard, T
    Buckingham, RE
    [J]. DIABETES, 2001, 50 (05) : 1021 - 1029